Jenburkt Pharmaceuticals Limited (BOM:524731)

Jenburkt Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	55.77	73.65	41.25	36.6	50.31
Short-Term Investments	-	417.39	157.79	698.44	458.25	415.55
Cash & Short-Term Investments	473.16	473.16	231.43	739.69	494.84	465.86
Cash Growth	104.45%	104.45%	-68.71%	49.48%	6.22%	-10.42%
Accounts Receivable	-	243.57	207.35	194.75	169.62	152.07
Other Receivables	-	53.95	11	50.02	42.28	21.31
Receivables	-	298.15	218.87	245.67	213.08	175.28
Inventory	-	138.1	88.8	85.66	83.38	98.98
Prepaid Expenses	-	11.89	11.59	6.77	4.59	5.53
Other Current Assets	-	29.59	14.61	19.49	15.02	13.39
Total Current Assets	-	950.89	565.32	1,097	810.91	759.04
Property, Plant & Equipment	-	653.4	547.06	112.14	112.19	113.05
Long-Term Investments	-	580.55	765.4	173.9	344.09	415.71
Other Intangible Assets	-	2.41	2.28	3.88	1.87	3.06
Long-Term Deferred Tax Assets	-	23.99	14.69	7.98	4.25	3.71
Other Long-Term Assets	-	48.82	66.93	255.51	144.23	133.59
Total Assets	-	2,260	1,962	1,651	1,418	1,429

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	81	81.55	62.57	60.97	71.1
Accrued Expenses	-	65.93	16.04	9.31	2.55	2.59
Short-Term Debt	-	-	19.79	-	24.39	58.15
Current Portion of Leases	-	6.49	4.23	-	4.89	4.51
Current Income Taxes Payable	-	11.38	2.86	16.41	3.37	0.77
Other Current Liabilities	-	66.68	63.72	75.49	61.46	75.67
Total Current Liabilities	-	231.47	188.19	163.79	157.62	212.8
Long-Term Leases	-	18.4	14.92	-	-	4.89
Long-Term Deferred Tax Liabilities	-	9.76	10.87	7.9	7.18	8.56
Other Long-Term Liabilities	-	30.1	30.1	29.91	29.43	29.43
Total Liabilities	-	289.72	244.09	201.59	194.22	255.67

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	44.13	44.13	44.13	44.13	45.89
Retained Earnings	-	1,935	1,657	1,375	1,165	1,119
Comprehensive Income & Other	-	-8.85	16.76	30.62	15.25	9.2
Shareholders' Equity	1,970	1,970	1,718	1,449	1,224	1,174
Total Liabilities & Equity	-	2,260	1,962	1,651	1,418	1,429

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	24.88	24.88	38.94	-	29.28	67.55
Net Cash (Debt)	448.28	448.28	192.5	739.69	465.57	398.31
Net Cash Growth	132.88%	132.88%	-73.98%	58.88%	16.89%	-15.15%
Net Cash Per Share	101.58	101.57	43.62	167.61	101.97	86.79
Filing Date Shares Outstanding	4.41	4.41	4.41	4.41	4.41	4.59
Total Common Shares Outstanding	4.41	4.41	4.41	4.41	4.41	4.59
Working Capital	-	719.43	377.12	933.49	653.29	546.24
Book Value Per Share	446.47	446.47	389.23	328.42	277.32	255.77
Tangible Book Value	1,968	1,968	1,715	1,446	1,222	1,171
Tangible Book Value Per Share	445.92	445.92	388.71	327.54	276.90	255.10
Buildings	-	125.58	117.96	107.24	103.86	101.39
Machinery	-	234.37	237.32	206.45	193.64	191.2
Construction In Progress	-	461.19	402.77	12.41	9.57	2.12

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error